CDTX stock · KEYS stock

CDTX vs KEYS

Cidara Therapeutics Inc (CDTX) versus Keysight Technologies Inc (KEYS) — a side-by-side from cached financials, not a winner call.

Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.

Keysight Technologies Inc (KEYS) is a scientific & technical instruments company listed on US.

Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.

Latest reported KEYS revenue for 2024-10-31 was $4.98B. Net income was $614.0M. Revenue was down 8.9% from 2023-10-31 to 2024-10-31. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.

CDTX currently screens at market cap $6.96B. KEYS currently screens at market cap $59.84B and trailing P/E 56.5.

Not investment advice. Open the CDTX and KEYS stock pages for the full models.

Not investment advice.

Popular Stock Comparisons